The closing of the offering is expected to occur on or about February 4, 2019, subject to the satisfaction of customary closing conditions.
H.C. Wainwright and Co. is acting as the exclusive placement agent for the offering.
The gross proceeds to the company, before deducting placement agent fees and other offering expenses, are expected to be approximately USD 5.5m.
Co-Diagnostics intends to use the net proceeds from this offering for expansion of existing initiatives in the infectious disease testing and agrigenomics verticals, to further develop and commercialise applications of its technology in the growing liquid biopsy and next-gen sequencing markets, to expand its sales efforts, and for working capital and other general corporate purposes.
The shares of common stock are being offered by Co-Diagnostics pursuant to a "shelf" registration statement on form S-3 that was originally filed on August 14, 2018 and declared effective by the Securities and Exchange Commission on September 7, 2018, and the base prospectus contained therein (File No. 333-226835).
The offering of the shares of common stock will be made only by means of a prospectus supplement that forms a part of the registration statement.
Co-Diagnostics, a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets a new, state-of-the-art diagnostics technology.
The company's technology is utilised for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA).
Co-Diagnostics also uses its proprietary technology to design specific tests to locate genetic markers for use in industries other than infectious disease and license the use of those tests to specific customers.
Quanterix partners with leading health networks for Alzheimer's diagnosis advancements
Precision BioSciences reports FDA pre-IND feedback for PBGENE-HBV
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences
Ondine Biomedical's Steriwave shows promise in nasal pathogen reduction
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial
AstraZeneca agrees acquisition of Icosavax
Versameb names new chairman of the board
Kling Bio appoints Dr Stefano Gullà as chief scientific officer